Bliss GVS Pharma Limited — Board Meeting, 28-01-2025: Outcome of Board Meeting

The Board of Bliss GVS Pharma Limited has approved the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2024. Total revenue for the quarter stood at ₹57.48 crore, with a net profit after tax of ₹6.32 crore. The board also reviewed the agenda for the issuance of Sweat Equity Shares, deciding on further steps for future implementation. This strategic move indicates a focus on employee engagement while boosting company growth potential.